Endonovo Therapeutics Overview
Latest ROE for Endonovo Therapeutics: 7.52% — see history and peer comparisons.
Get informed when a big investor buys or sells
+ Follow7.52%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
The latest ROE for ENDV is 7.52%. That is above the Healthcare sector average of -75.59%. Investors often review this figure alongside Endonovo Therapeutics's historical trend and sector peers before judging valuation or financial health.
Against Healthcare companies, ENDV currently prints 7.52% for ROE, while the sector average sits near -75.59%. That is roughly 110.0% above the sector mean. Large gaps often invite a closer look at Endonovo Therapeutics's growth, margins, and balance sheet.
Return on Equity shows how effectively Endonovo Therapeutics converts resources into returns. At 7.52%, ENDV may look efficient or underperforming depending on peer benchmarks and trend direction. Pair the percentage with revenue growth and leverage for a fuller health check.
After noting ENDV's ROE (7.52%), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
This page's peer comparison chart is the fastest way to stack Endonovo Therapeutics's ROE against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.
